Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Vertex Pharmaceuticals (VRTX) announced positive Phase 3 RAINIER trial results for povetacicept in IgA nephropathy, published in NEJM and presented at ASN Kidney Week 2026. The drug met primary and secondary endpoints, showing a 52.0% reduction in proteinuria at Week 36. Vertex aims for FDA accelerated approval by November 30, 2026. The company also highlighted patient preference for povetacicept's autoinjector and dosing schedule. Additional clinical studies are underway.

Vertex Pharmaceuticals (VRTX) reported positive Phase 3 trial results for povetacicept in treating IgAN, meeting primary endpoints. The drug showed a 52.0% reduction in proteinuria vs. 49.8% for placebo. The FDA set a Nov. 30, 2026, decision date for accelerated approval. The trial had no serious adverse events, and Vertex is also testing the drug for other conditions.

Vertex's Phase 3 RAINIER trial of povetacicept in IgA nephropathy (IgAN) met its primary endpoint, showing significant proteinuria reduction. The drug demonstrated favorable safety and convenient at-home dosing. Vertex plans an FDA submission with a PDUFA target date of November 30. The company also presented patient preference data for the autoinjector device and announced new clinical trials.

Vertex Pharmaceuticals reported positive interim results from its Phase 3 RAINIER trial, showing that povetacicept reduced proteinuria by 49.8% compared to placebo. The FDA is reviewing the drug for accelerated approval with a PDUFA date of November 30, 2026.

Vertex Pharmaceuticals' povetacicept reduced proteinuria by 52% vs. 4.3% for placebo in IgA nephropathy patients in the RAINIER trial. FDA accepted a BLA for povetacicept with a PDUFA date of November 30, 2026. The drug also decreased Gd-IgA1 and resolved hematuria, with a safety profile similar to placebo.

Vertex Pharmaceuticals (VRTX) completed its largest acquisition, Crinetics, for $10B, gaining Palsonify and Atumelnant. Palsonify, for acromegaly, and Atumelnant, for CAH and Cushing's syndrome, could generate over $5B in peak revenue. Vertex aims to diversify beyond cystic fibrosis with these and other pipeline drugs.